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Screening newborns for cystic fibrosis (CF) is considered to be an ethical undertaking in regions with a significant incidence of the condition.
Current screening protocols result in recognition of infants with an equivocal diagnosis. A survey of European practice suggested inconsistencies
in the evaluation and management of these infants.
We have undertaken a consensus process using a modified Delphi method. This has enabled input of CF specialists from a wide geographical
area to a rigorous process that has provided a clear pathway to a consensus statement. A core group produced 21 statements, which were modified
over a series of three rounds (including a meeting arranged at the European CF Conference). A final document of 19 statements was produced, all
of which achieved a satisfactory level of consensus. The statements cover four themes; sweat testing, further assessments and investigations,
review arrangements and database.
This consensus document will provide guidance to CF specialists with established screening programmes and those who are in the process of
implementing newborn screening in their region.
Crown Copyright © 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.Keywords: Cystic fibrosis; Neonatal screening; Management; Sweat test; Gene analysis1. Introduction
There is a good agreement that screening newborns for cystic
fibrosis (CF) is a valid and ethical undertaking in regions such as
Europe with a significant incidence of the condition [1]. Protocols
for screening rely on the recognition that infants with CF have a
high level of immuno-reactive trypsinogen (IRT) in their blood
in the first week of life [2]. This test is sensitive but has poor
specificity and therefore a second tier of investigations is
necessary to identify those infants most at risk of CF [3]. In
most newborn screening (NBS) protocols, this involves examin-
ing for commonmutations of theCystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene which are associated with
CF [4]. Such protocols will result in the recognition of carrier
infants and data from well-established NBS programmes suggest
that more carriers are recognised by NBS than might be expected
for the incidence of CF in that population [5]. It has been
concluded that this reflects the fact that carriers have a higher IRT
than the non-carrier population and this is supported by data from
population studies [6]. In most NBS protocols infants recognised
as putative carriers have further assessment including a sweat test
to exclude CF [4].
Another significant challenge of NBS for CF is the recognition
of infants with an equivocal diagnosis [4,7]. This reflects the
heterogeneous nature of the condition and poses a challenge toCF
teams. Infants with one recognised CFTR mutation or persistent
hypertrypsinaemia may have an intermediate sweat test result or
an infant may be recognised with two CFTR mutations, one or
both of which have unclear phenotypic consequences [7]. There
is significant variability in the evaluation and management of
these infants with an equivocal diagnosis [3,8]. We have used amodified Delphi method to form a consensus on the evaluation
and management of these infants [9]. The Delphi method is a
recognised technique that provides a formal strategy to gather
expert opinion and form a consensus when there is a lack of high
quality evidence onwhich to base practice. The method facilitates
the inclusion of experts from a geographically disperse region and
establishes a framework which makes it possible to clearly trace
back how the group came to a decision.
2. Methods
Twenty-one preliminary statements were composed by a
core group of experts in the field (CC, AM and KWS), taking
into account the results of a survey of European practice [4].
The statements covered four thematic areas; sweat testing,
further assessments and investigations, review arrangements
and database. Two European Cystic Fibrosis Society (ECFS)
working groups (the Diagnostic Network (ECFDN) and the
Neonatal Screening Working Group) were approached and their
members, which include clinicians, biochemists and geneticists,
contacted by email. Additional invitations were made to in-
crease multidisciplinary input. Consensus was determined a
priori to be 80% of ratings providing agreement with the
statement (considered sufficient for this type of study) [9].
For round one, specialists were asked to rate their opinion of
each statement by choosing one of three options; 1) agree,
2) could agree if reworded or 3) disagree. Specialists choosing
options 2) or 3) were asked for comments and also suggestions
for alternative or modified statements.
After round one, statements not achieving consensus (or
achieving consensus with provisos) were modified by the core
Fig. 1. The stages and outcomes of the modified Delphi method.
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by respondents. These modified statements were then circulated
in round two together with the original statements, the group
ratings from round one and a summary of comments.
Individuals who replied to round one were included in round
two.
Following round two, statements not achieving consensus
were presented and discussed in the European Cystic Fibrosis
Neonatal Screening Working Group meeting at the 30th
European Cystic Fibrosis Society Conference, Belek, Turkey
in 2007. This meeting involved members of the consensus group
(although not all) and other CF Specialists. The entire consensus
document was presented, but the focus of the meeting was on
statements that had not achieved consensus. This facilitated an
open discussion that enabled deeper reflection on the issues
around these statements. Statements were subsequently revised
by the core group taking into account the discussions at this
meeting and comments already received from round two. The
revised statements were again circulated in round three to all
respondents together with the original statements, the level of
agreement from round two and respondents' comments (Fig. 1).
Four appendices were constructed to provide further information
and background to the statements (Table 1) and cover a) Sweat




Forty-one responses from specialists in 11 European
countries were received for round one. A consensus of over
80% was achieved on twelve of 21 statements. A further five
statements were approaching consensus with greater than 60%
agreement. Four statements had poor level of agreement
(b60%).
3.2. Round two
Nine statements not achieving consensus in round one and
three that did with provisos were revised by the core group,
following analysis of respondents' comments. Respondents were
asked to rate their agreement with both the revised and modified
statements. Thirty-eight responses were obtained following round
two. A consensus of greater than 80% was achieved on a further
ten statements. Consensus was not achieved in two.
3.3. Round three
The two statements not achieving consensus were discussed
at the ECFS Screening Working Group Meeting. Taking into
account this meeting and respondents comments, it was clear
that modification and combination of four statements were
required to obtain consensus, reducing the number of statements
from twenty one to nineteen. Thirty-four responses were ob-
tained to round three and consensus was achieved on all nineteen
statements (Table 1). An algorithm was developed from theconsensus statements (Fig. 2). Seven specialists who responded
to round one did not respond to round three (17% attrition rate).
3.4. Specific issues and comments
3.4.1. Clinic size
Original statements for round one defined specialist CF
clinic size greater than 100 patients and achieved consensus.
Despite this, several respondents discussed the size of clinics
Table 1
Nineteen statements at the end of the consensus process
1 An infant with one or more raised IRT measurements and an equivocal sweat test (sweat Cl− ≥30 and b60 mmol L−1) requires assessment
and review in a specialist CF clinic (with N50 patients).
2 An infant with two CFTR gene changes (one of which has unclear clinical significance) and a normal sweat test requires assessment and review
in a specialist CF clinic (N50 patients).
3 In these cases (infants from statements 1 and 2) a repeat sweat test should be undertaken in a centre with suitable experience (N150 sweat tests pa) of a validated
technique for measuring sweat chloride ( Appendix A).
4 Infants from statement 1, who have a normal repeat sweat test in an accredited centre (sweat Cl− b30 mmol l−1), do not require further clinical review (negative CF
screening test).
5 Extended gene analysis must be undertaken in infants with two equivocal sweat tests and one or no CFTR mutations recognised ( Appendix B).
6 Infants with one or more raised IRT measurements, one CFTR mutation and a normal sweat test (Cl− b30) do not require extended gene analysis.
7 Infants with one or more raised IRT measurements, one CFTR mutation and a normal sweat test (Cl− b30) do not require review
in a CF clinic (negative CF screening test). Appropriate advice regarding carrier status should be given.
8 Infants with two equivocal sweat tests require detailed baseline assessment for respiratory disease (airways culture and chest radiograph).
Further investigations may be indicated as determined by the clinical situation (for example, chest CT scan, and bronchoscopy).
9 Infants with two equivocal sweat tests require detailed baseline assessment for non-respiratory disease (fecal elastase). Other investigations as clinically indicated.
10 Infants with two equivocal sweat tests and any clinical evidence supportive of a CF diagnosis should have regular follow up in a CF specialist clinic ( Appendix C).
11 Infants with two equivocal sweat tests, one or no CF causing mutations and no clinical evidence of CF should be considered for further investigation
of a physiological defect in a centre with appropriate experience (Appendix D).
12 Infants with two equivocal sweat tests, one or no CF causing mutation, no clinical evidence of CF and evidence of ion transport defect on further testing
should be followed up in a specialist CF clinic.
13 All infants with two equivocal sweat tests, one or no CF causing mutation, no clinical evidence of CF should be reviewed in a specialist CF clinic
with a repeat sweat test at 6–12 months of age.
14 Infants with two CFTR gene changes (as statement 2) but a normal sweat test (at least one performed in a centre with adequate experience,
as per statement 3) should have detailed clinical assessment (as 8 and 9).
15 Infants with two CFTR gene changes (as statement 2), a normal sweat test and any clinical evidence of CF should have regular follow up in a CF specialist clinic.
16 Infants with two CFTR gene changes (as statement 2), a normal sweat test and no clinical evidence of CF should be considered for further
investigation of a physiological defect in a centre with appropriate experience ( Appendix D).
17 Infants with two CFTR gene changes (as statement 2), a normal sweat test, no clinical evidence of CF but evidence of abnormal ion transport
should have regular follow up in a specialist CF clinic.
18 Infants with two CFTR gene changes (as statement 2), a normal sweat test and no clinical evidence of CF should be reviewed in a specialist CF
clinic with a repeat sweat test at 6–12 months.
19 Clinical and demographic information on all infants with an equivocal diagnosis should be entered onto a database or registry
(pending consent from legal guardian).
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Europe specialist CF clinics are traditionally smaller. Overall
however it was felt beneficial to include a proposed number and
the statements were modified to “specialist CF clinic (with N50
patients)”, which again achieved consensus.
3.4.2. Sweat test
The sweat testing experience of the centre was suggested at
greater than 150 sweat tests performed annually and this
achieved consensus in round one (Statement 3). See also
Appendix A.
3.4.3. Equivocal sweat test result
All infants considered by the guideline will have one or more
raised IRT. When these infants subsequently have an equivocal
sweat test result they require assessment and review in a
specialist CF clinic with a repeat sweat test (Statement 1). If the
sweat test in an accredited centre remains equivocal (chloride,
30–60 mmol L−1) further investigation is required. This should
include extended gene analysis if one or no CFTR mutations
have been identified (Statement 5) and baseline assessment for
respiratory and non-respiratory disease (Statements 8 and 9). If
these infants show any clinical evidence supportive of the
diagnosis of CF they should have regular follow up in a
specialist CF clinic (Statement 10). If there is no clinicalevidence of CF they should be reviewed in a specialist CF clinic
with sweat test repeated between 6 and 12 months of age
(Statement 13).
3.4.4. What constitutes a negative screening result?
Infants who have equivocal sweat test (chloride 30–60mmol/l)
that on repeat test is found to be normal (b30mmol/l) do not
require further clinical review (Statement 4). Thiswas agreed to be
a negative screening result i.e. CF not suspected (85%, round one).
Infants who have one or more raised IRT measurements,
one CFTR mutation and a normal sweat test have a negative
screening test (Statement 7). This statement was approaching
consensus in round one (71%). Following respondents com-
ments, the statement was modified to advise discussion of
carrier status and this achieved 92% consensus in round two.
3.4.5. Extended gene analysis
Extended gene analysis is indicated when an infant has had
two equivocal sweat test results and only one or no CFTR
mutation has been identified on the local common mutation
panel (Statement 5, 85% consensus round one) (Appendix B).
Extended gene analysis should not be performed in infants with
one or more raised IRT, one CFTR mutation and a normal sweat
test. These infants have a negative screening result (Statement 6,
80% consensus round one).
Fig. 2. The pathway of interventions that infants with an equivocal diagnosis may follow according to the results of this consensus process. The two distinct
presentations of these infants (equivocal sweat test or two CFTR gene mutations of unclear clinical significance) represent the starting points at the top of the figure.
The progress of the infant is then tracked following the repeat sweat test in an experienced centre. Subsequent interventions depend to some degree on the result of the
repeat sweat test. The numbers indicate the consensus statement (Table 1) that corresponds to that part of the pathway. An important point to note is that infants who
enter the pathway with an equivocal sweat test and then have a normal repeat sweat test do not require extended gene analysis or further clinical review (although some
may require advice regarding carrier status). Clinical assessment for evidence of CF is considered important with respect to determining subsequent review
arrangements (infants with any clinical evidence supporting a CF diagnosis should be seen in a specialist CF clinic). ⁎ One of which has unclear clinical significance.
† In a centre with suitable experience (Appendix A). ‡ Normal=sweat Cl b30 mmol l−1, equivocal=sweat Cl≥30 and b60 mmol l−1, raised=sweat Cl≥60 mmol l−1.
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disease
It was agreed that infants who had two equivocal sweat test
results or who have two CFTR gene changes and a normal
sweat test should have baseline clinical assessment (Statements
8, 9 and 14). In round one, baseline assessment for respiratory
disease included CT scan and bronchoscopy and this statement
achieved a poor level of agreement (41%). The statement was
modified to include these investigations only when indicated by
the clinical situation and 89% agreement was achieved in the
second round (Statement 8). Similarly a significant number felt
that some of the proposed non-respiratory investigations
were unnecessary and this statement was changed accordingly
(to faecal elastase with other investigations as clinically in-
dicated). The statement achieved 92% agreement in round two
(Statement 9).
3.4.7. Further investigation of physiological defect
A number of measurements of transepithelial salt transport
exist that may help in investigating an equivocal diagnosisof CF. However, none have the face validity of sweat
electrolyte measurement and are essentially extensions of
research methodology. This was reflected in the variability of
responses to statements concerning further electrophysiolo-
gical investigation ranging from enthusiastic advocates to
confirmed sceptics. It was agreed with 83% consensus in
round two that infants who had two equivocal sweat tests
and no clinical evidence of CF should be considered for
further investigation of a physiological defect (Statement 11).
If there is evidence of ion transport defect even in the ab-
sence of clinical evidence of CF with only one CFTR muta-
tion these infants should be followed up in a specialist CF
clinic (Statement 12).
It proved difficult to obtain a consensus regarding the
subsequent management of infants who had no evidence of ion
transport defect. In the absence of consensus, these infants are
covered by Statement 13. This reflects a general anxiety that it
would be inappropriate to exclude a diagnosis of CF on the
basis of these measures alone, even when there is no clinical
suspicion following baseline assessment.
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unclear clinical significance
The term CFTR gene change was used in the statements to
highlight that these mutations have unclear phenotypic con-
sequences. Subsequently, an ECFS consensus has been achieved
on the use and interpretation of CF mutation analysis in clinical
practice and has concluded that the term “mutation” should be
used to define any molecular alteration in the DNA sequence of
theCFTR gene [10]. Therefore for the purposes of this process the
terms CFTR gene change and mutation are interchangeable. The
dilemma remains that a number of frequently recognised CFTR
gene mutations have unclear phenotypic consequence. The
situation in CF NBS is further exacerbated by the fact that some
CFTR mutations that are clearly “CF causing” can have little if
any phenotypic consequence in the first years of life, related to the
confounding impact of environment and other non-CFTR genes.
Therewas clear agreement that if these infants have any clinical
evidence of CF they should have regular follow up in a specialist
CF clinic, even with a normal sweat test result (Statement 15). If
there is no clinical evidence of CF they should be considered for
further investigation of ion transport defect (Statement 16) but
regardless should be reviewed in a specialist CF clinic with sweat
test repeated between 6 and 12 months of age (Statement 18). If
there is evidence of abnormal ion transport these infants should
have regular review in a specialist CF clinic (Statement 17).
4. Discussion
There is a good agreement that screening infants for CF is an
ethical undertaking in regions with a significant incidence of the
condition [1]. Unfortunately, current NBS protocols result in
recognition of infants with an equivocal diagnosis of CF. To
some degree this reflects the heterogeneity of the condition
and the sensitivity of the IRT measurement. Infants with an
equivocal diagnosis fall into two groups; those with intermediate
sweat electrolytes (above the level expected for this age group),
but no or one recognised CFTR gene mutation and those with
two CFTR gene mutations, one or both of which have unclear
long term phenotypic consequences.
Using a modified Delphi method, we have produced 19
statements that will act as a guide for CF teams in the evaluation
andmanagement of infants with an equivocal diagnosis following
newborn screening. Strengths of this process have been the
inclusive nature across a wide geographical area and a robust
framework that enables clear identification of decision making
pathways. From the consensus guideline, we have produced an
algorithm to aid clinicians involved in CF NBS programmes. It
was not the aim of this group to provide a diagnostic framework;
rather to provide a pragmatic guideline for the management and
evaluation of these infants. The end-points in the algorithm are
therefore functional rather than categorical (Fig. 2).
Although the majority of statements attained consensus in the
early phases of the process, some areas were more challenging.
The group meeting was an essential part of the Delphi process to
identify issues around these statements and achieve a final
consensus. These guidelines can be used in established screen-
ing regions and in those with emerging programmes to guidethe evaluation and management of this challenging clinical
dilemma.
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Appendix A
Notes on sweat testing
1) Sweat collection in infants is challenging [11].
2) Sweat collection and analysis should be undertaken in a
centre with adequate experience. CF physicians should be
guided by national standards. If these are not available,
consensus documents are available from the United Kingdom
(http://acb.org.uk/docs/sweat.pdf) and North America [11].
These suggest that a laboratory should be undertaking at least
50 tests per year; however for infants with an initial equivocal
result, the repeat sweat test should be done in a centre with
more experience (N150 sweat tests per year, Statement 3).
3) Two equivocal sweat test results may be available on the
same day that were undertaken in a suitably experienced
centre, in which case the infant should proceed along the
algorithm as described (Fig. 2).
4) Sweat chloride concentration remains the gold standard
analytical measure to confirm a diagnosis of CF [11].
5) Sweat sodium should not be used [11].
6) Sweat conductivity may have a role in excluding a diagnosis
of CF but does not have sufficient face validity in cases with
an initial equivocal result [11].
7) Sweat electrolyte values fall over the first 4 weeks of life
[12,13]. A sweat chloride value over 30 mmol L−1 should
prompt clinical review and a repeat sweat test [11].
Appendix B
Notes on extended DNA analysis
1. Further investigation of these infants should be undertaken
with close liaison with the local molecular genetics service.
The extent of DNA analysis should reflect the clinical
suspicion. Care should be taken in avoiding the situation
where gene changes (mutations) are recognised with unclear
phenotypic characterisation, although in most circumstances
this will be unavoidable, particularly as laboratories move
more quickly to comprehensive CFTR gene sequencing.
2. CFTR gene change is equivalent to CFTR mutation.
3. Further DNA analysis should be guided by the screening pro-
tocol (i.e., protocols that initially only examine for a limited
panel ofCFTRmutationswould prompt further DNA analysis).
4. Infants recognised to be compound heterozygotes for R117H
should have further characterisation of the poly T variant
region (and TG repeats if found to be on a 5T background)
[14,15]. Infants with R117H on a 7T background may have a
normal or equivocal sweat test. Long term clinical outcome is
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cialist input (as per statements 2, 14, 15, 16, 17 and 18) [7,16].
5. Some CFTR mutations that are clearly “CF causing” (in
particular, 3849+10 kb CNT) are associated with normal or
equivocal sweat electrolyte values. Close liaison with the local
molecular genetics service is needed to determine these infants.
6. Infants with persistent intermediate sweat electrolytes and clin-
ical features (Appendix C) should have extensive DNA anal-
ysis after discussion with the local molecular genetics service.
Appendix C











e. Abnormal chest shape
3. Chest radiograph changes
a. Overinflation
b. Increased markings
c. Areas of collapse or consolidation4. Chest high resolution computerised tomogram (HRCT)
changes
a. Air trapping
b. Early evidence of airway inflammation/bronchiectasis




1. Clinical evidence of malabsorption
a. Meconium ileus
b. Poor weight gain
c. Distended abdomen
d. Loose offensive stool
e. Poor head growth
f. Rectal prolapse
2. Laboratory evidence of malabsorption
a. Low fecal elastase (or chymotrypsin)
b. Positive fat microscopy
c. Low fat soluble vitamin levels
3. Radiological evidence of pancreatic disease
a. Pancreatic calcification on Abdominal radiograph
b. Pancreatic fibrosis on abdominal ultrasound scan
4. Liver disease
a. Prolonged cholestatic jaundice
b. Elevated liver enzymes (ALT/AST)
c. Abnormal liver appearance on ultrasound scan
5. Salt loss
6. Absence of the vas deferensAppendix D
Further physiological testing.
A number of electrophysiological techniques are available to demonstrate the salt transport defect that characterises CF. These are
undertaken in specialist centres. None have the face validity of sweat testing or genotype analysis, but may provide useful additional
information in equivocal cases. Some of these tests are particularly challenging in infants.Test Technical details What it involves for the infant AvailabilityaNasal Potential
Difference (PD)Ion transport across airway epithelium can
be assessed by measuring the baseline PD.
The impact on the PD of perfusing different
solutions and drugs provides further
information to differentiate CF from
non-CF recordings.The exploring electrode is placed in the nose.
A reference electrode is placed either
subcutaneously or over abraded skin on the
forearm. Solutions are perfused through the
exploring electrode into the nose and can
be swallowed.Very few centres are able to undertake
this measurement in infants although
it is more widely available in older
children and adults.Intestinal Current
Measurements (ICM)A biopsy is mounted in the laboratory in a
device (Ussing chamber) that enables
measurement of transepithelial ion transport.
Various aspects of ion transport can be
examined.Biopsy of rectal mucosa. This procedure
is painless and well tolerated by young
infants. Does not require general
anaesthesia or sedation.This technique requires a dedicated
laboratory service with highly skilled
technicians. Available in limited
number of centres in Europe.Small bowel biopsy Similar measures of transepithelial
transport processes can be
undertaken in the laboratory on upper
gastro-intestinal (GI) mucosal
biopsies.Upper GI biopsy; requires general
anaesthesia in most cases.Limited (only currently
available in Sheffield,
UK; contact Prof Chris Taylor).aFor details of centres in Europe that undertake appropriate electrophysiological investigations on infants, contact Dr Michael Wilschanski, chair of the European
CF Society Diagnostic Network (michaelwil@hadassah.org.il).
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